Lv11
60 积分 2025-05-25 加入
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial
2个月前
已完结
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial
2个月前
已完结
Management of ocular toxicity in patients with gynecologic cancer receiving novel antibody–drug conjugates: a narrative review
2个月前
已完结
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial
2个月前
已完结
Immune checkpoint inhibitor myocarditis—a score to tell you more
3个月前
已完结
Corneal Changes From Antibody-Drug Conjugates
5个月前
已完结
Management of Advanced Penile Cancer
6个月前
已完结
Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study
6个月前
已完结
New Therapeutic Horizons for Advanced or Metastatic Penile Cancer
6个月前
已关闭
Assessment of PD-L1, TROP2, and nectin-4 expression in penile squamous cell carcinoma
6个月前
已完结
皖公网安备34019202002308
